1. Jalali J, Ghasemzadeh Rahbardar M. Ameliorative effects of Portulaca oleracea L. (purslane) on the metabolic syndrome: A review. J Ethnopharmacol 2022; 299:115672.
2. Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel insights into the pathogenesis and management of the metabolic syndrome. Pediatr Gastroenterol Hepatol Nutr 2020; 23:189-230.
3. Yahyazadeh R, Ghasemzadeh Rahbardar M, Razavi BM, Karimi G, Hosseinzadeh H. The effect of Elettaria cardamomum (cardamom) on the metabolic syndrome: Narrative review. Iran J Basic Med Sci 2021; 24:1462-1469.
4. Fadishei M, Ghasemzadeh Rahbardar M, Imenshahidi M, Mohajeri A, Razavi BM, Hosseinzadeh H. Effects of Nigella sativa oil and thymoquinone against bisphenol A-induced metabolic disorder in rats. Phytother Res 2021; 35:2005-2024.
5. Yarmohammadi F, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Effect of eggplant (Solanum melongena) on the metabolic syndrome: A review. Iran J Basic Med Sci 2021; 24:420-427.
6. Oskouei Z, Ghasemzadeh Rahbardar M, Hosseinzadeh H. The effects of Dendrobium species on the metabolic syndrome: A review. Iran J Basic Med Sci 2023; 26:738-752.
7. Ardakanian A, Ghasemzadeh Rahbardar M, Omidkhoda F, Razavi BM, Hosseinzadeh H. Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats. Iran J Basic Med Sci 2022; 25:198-207.
8. Najafi N, Mehri S, Ghasemzadeh Rahbardar M, Hosseinzadeh H. Effects of alpha lipoic acid on metabolic syndrome: A comprehensive review. Phytother Res 2022; 36:2300-2323.
9. Salehsari A, Ghasemzadeh Rahbardar M, Razavi BM, Hosseinzadeh H. Investigating the effect of zeaxanthin on olanzapine-induced metabolic disorders in rats. Avicenna J Phytomed 2024.
10. Naraki K, Ghasemzadeh Rahbardar M, Ajiboye BO, Hosseinzadeh H. The effect of ellagic acid on the metabolic syndrome: A review article. Heliyon 2023; 9:e21844.
11. Dandekar P, Wasewar KL. Experimental investigation on extractive separation of vanillic acid. Chem Data Collect 2020; 30:100564.
12. Ingole A, Kadam MP, Dalu AP, Kute SM, Mange PR, Theng VD, et al. A review of the pharmacological characteristics of vanillic acid. J Drug Deliv Ther 2021; 11:200-204.
13. Salau VF, Erukainure OL, Ibeji CU, Olasehinde TA, Koorbanally NA, Islam MS. Vanillin and vanillic acid modulate anti-oxidant defense system via amelioration of metabolic complications linked to Fe 2+-induced brain tissues damage. Metab Brain Dis 2020; 35:727-738.
14. Ziadlou R, Barbero A, Martin I, Wang X, Qin L, Alini M, et al. Anti-inflammatory and chondroprotective effects of vanillic acid and epimedin C in human osteoarthritic chondrocytes. Biomolecules 2020; 10:932.
15. Yalameha B, Nejabati HR, Nouri M. Cardioprotective potential of vanillic acid. Clin Exp Pharmacol Physiol 2023; 50:193-204.
16. Alamri ES, El Rabey HA, Alzahrani OR, Almutairi FM, Attia ES, Bayomy HM, et al. Enhancement of the protective activity of vanillic acid against tetrachloro-carbon (CCl4) hepatotoxicity in male rats by the synthesis of silver nanoparticles (AgNPs). Molecules 2022; 27:8308.
17. Mohan S, Nair A, Poornima M, Raghu K. Vanillic acid mitigates hyperinsulinemia induced er stress mediated altered calcium homeostasis, mams distortion and surplus lipogenesis in Hepg2 cells. Chem Biol Interact 2023; 375:110365.
18. Shekari S, Khonsha F, Rahmati-Yamchi M, Nejabati HR, Mota A. Vanillic acid and non-alcoholic fatty liver disease: a focus on AMPK in adipose and liver tissues. Curr Pharm Des 2021; 27:4686-4692.
19. Khalid M, Alkaabi J, Khan MA, Adem A. Insulin signal transduction perturbations in insulin resistance. Int J Mol Sci 2021; 22:8590.
20. Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol 2020; 10:1607.
21. Hudish LI, Reusch JE, Sussel L. β Cell dysfunction during progression of metabolic syndrome to type 2 diabetes. J Clin Invest 2019; 129:4001-4008.
22. Yue X, Han T, Hao W, Wang M, Fu Y. SHP2 knockdown ameliorates liver insulin resistance by activating IRS‐2 phosphorylation through the AKT and ERK1/2 signaling pathways. FEBS Open Bio 2020; 10:2578-2587.
23. Guven B, Onay-Besikci A. Past and present of beta arrestins: A new perspective on insulin secretion and effect. Eur J Pharmacol 2023:175952.
24. White MF, Kahn CR. Insulin action at a molecular level–100 years of progress. Mol Metab 2021; 52:101304.
25. da Costa RM, Rodrigues D, Pereira CA, Silva JF, Alves JV, Lobato NS, et al. Nrf2 as a potential mediator of cardiovascular risk in metabolic diseases. Front Pharmacol 2019; 10:382.
26. Vona R, Gambardella L, Cittadini C, Straface E, Pietraforte D. Biomarkers of oxidative stress in metabolic syndrome and associated diseases. Oxid Med Cell Longev 2019; 2019:8267234.
27. Gupta N, Mukerjee A, Mishra SB. Design, synthesis and molecular docking of vanillic acid derivatives as amylolytic enzyme inhibitors. Pharm Chem J 2021; 55:427-435.
28. Saravanan V, Venkatraman A, Mohideen HS. Molecular docking of active compounds from Phoenix pusilla root extract against antidiabetic and anti-inflammatory drug targets. J App Biol Biotech 2021; 9:26-30.
29. Sansenya S, Payaka A. Inhibitory potential of phenolic compounds of Thai colored rice (Oryza sativa L.) against α‐glucosidase and α‐amylase through in vitro and in silico studies. J Sci Food Agric 2022; 102:6718-6726.
30. Garba MS, Bouderbala S. Seed from olive cake prevents hyperglycemia, hyperlipidemia, and oxidative stress in dexamethasone-induced diabetes rats. Nor Afr J Food Nutr Res 2024; 8:135-148.
31. Mohan S, George G, Raghu KG. Vanillic acid retains redox status in HepG2 cells during hyperinsulinemic shock using the mitochondrial pathway. Food Biosci 2021; 41:101016.
32. Sreelekshmi M, Raghu KG. Vanillic acid mitigates the impairments in glucose metabolism in HepG2 cells through BAD–GK interaction during hyperinsulinemia. J Biochem Mol Toxicol 2021; 35:1-8.
33. Naganna CM, Prasad KY, Mahendra VP, Ganesan P, Kumar R. Vanillic acid potentiates insulin secretion and prevents pancreatic β-cells cytotoxicity under H(2)O(2)-induced oxidative stress. Mol Biol Rep 2023; 50:1311-1320.
34. Chang WC, Wu JS, Chen CW, Kuo PL, Chien HM, Wang YT, et al. Protective effect of vanillic acid against hyperinsulinemia, hyperglycemia and hyperlipidemia via alleviating hepatic insulin resistance and inflammation in high-fat diet (HFD)-fed rats. Nutrients 2015; 7:9946-9959.
35. Alhadid A, Bustanji Y, Harb A, Al-Hiari Y, Abdalla S. Vanillic acid inhibited the induced glycation using in vitro and in vivo models. Evid Based Complementary Altern Med 2022; 2022:7119256.
36. Vinothiya K, Ashokkumar N. Modulatory effect of vanillic acid on anti-oxidant status in high fat diet-induced changes in diabetic hypertensive rats. Biomed Pharmacother 2017; 87:640-652.
37. Ji G, Sun R, Hu H, Xu F, Yu X, Priya Veeraraghavan V, et al. Vannilic acid ameliorates hyperglycemia-induced oxidative stress and inflammation in streptozotocin-induced diabetic rats. King Saud Univ Sci 2020; 32:2905-2911.
38. Kumari S, Kamboj A, Wanjari M, Sharma AK. Nephroprotective effect of Vanillic acid in STZ-induced diabetic rats. J Diabetes Metab Disord 2021; 20:571-582.
39. Khairnar S, Pawar S, Patil V, Rudrapal M. Effect of vanillic acid in streptozotocin induced diabetic neuropathy. Asian J Biol Life Sci 2021; 9:306-312.
40. Singh B, Kumar A, Singh H, Kaur S, Arora S, Singh B. Protective effect of vanillic acid against diabetes and diabetic nephropathy by attenuating oxidative stress and upregulation of NF-κB, TNF-α and COX-2 proteins in rats. Phytother Res 2022; 36:1338-1352.
41. Hedayatnia M, Asadi Z, Zare-Feyzabadi R, Yaghooti-Khorasani M, Ghazizadeh H, Ghaffarian-Zirak R, et al. Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids Health Dis 2020; 19:42.
42. Nagarthna P, HarshaVardhini N, Bashir B, Sridhar K. Hyperlipidemia and its treatment: A review. J Adv Sci Res 2020; 11:1-6.
43. Iqbal J, Al Qarni A, Hawwari A, Alghanem AF, Ahmed G. Metabolic syndrome, dyslipidemia and regulation of lipoprotein metabolism. Curr Diabetes Rev 2018; 14:427-433.
44. Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. J Clin Invest 2022; 132:e148559.
45. Duran EK, Pradhan AD. Triglyceride-rich lipoprotein remnants and cardiovascular disease. Clin Chem 2021; 67:183-196.
46. Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport: Basic mechanisms and their roles in vascular health and disease. Circ Res 2019; 124:1505-1518.
47. Ouyang S, Mo Z, Sun S, Yin K, Lv Y. Emerging role of Insig-1 in lipid metabolism and lipid disorders. Clin Chim Acta 2020; 508:206-212.
48. Dong X, Zhu Y, Wang S, Luo Y, Lu S, Nan F, et al. Bavachinin inhibits cholesterol synthesis enzyme FDFT1 expression via AKT/mTOR/SREBP-2 pathway. Int Immunopharmacol 2020; 88:106865.
49. Ugwor EI, Ugbaja RN, James AS, Dosumu OA, Thomas FC, Ezenandu EO, et al. Inhibition of fat accumulation, lipid dysmetabolism, cardiac inflammation, and improved nitric oxide signalling mediate the protective effects of lycopene against cardio-metabolic disorder in obese female rats. Nutr Res 2022; 104:140-153.
50. Čolak E, Pap D. The role of oxidative stress in the development of obesity and obesity-related metabolic disorders. J Med Biochem 2021; 40:1-9.
51. Gianazza E, Brioschi M, Martinez Fernandez A, Casalnuovo F, Altomare A, Aldini G, et al. Lipid peroxidation in atherosclerotic cardiovascular diseases. Antioxid Redox Signal 2021; 34:49-98.
52. Kumari R, Kumar S, Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr 2019; 13:2409-2417.
53. Speelman T, Dale L, Louw A, Verhoog NJ. The association of acute phase proteins in stress and inflammation-induced T2D. Cells 2022; 11:2163-2182.
54. Shi J, Fan J, Su Q, Yang Z. Cytokines and abnormal glucose and lipid metabolism. Front Endocrinol 2019; 10:703.
55. Püschel GP, Klauder J, Henkel J. Macrophages, low-grade inflammation, insulin resistance and hyperinsulinemia: A mutual ambiguous relationship in the development of metabolic diseases. J Clin Med 2022; 11:4358-4387.
56. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 2021; 320:C375-C391.
57. Prince PS, Dhanasekar K, Rajakumar S. Preventive effects of vanillic acid on lipids, bax, bcl-2 and myocardial infarct size on isoproterenol-induced myocardial infarcted rats: A biochemical and in vitro study. Cardiovasc Toxicol 2011; 11:58-66.
58. Kumar S, Prahalathan P, Saravanakumar M, Raja B. Vanillic acid prevents the deregulation of lipid metabolism, endothelin 1 and up regulation of endothelial nitric oxide synthase in nitric oxide deficient hypertensive rats. Eur J Pharmacol 2014; 743:117-125.
59. Obydah WO, Shaker GA, Samir SM, El Bassiony SF, Abd El Moneim HA. Effect of vanillic acid and exercise training on fatty liver and insulin resistance in rats: Possible role of fibroblast growth factor 21 and autophagy. Physiol Int 2021.
60. Vishnu KV, Ajeeshkumar KK, Lekshmi RG, Chatterjee NS, Ganesan B, Anandan R, et al. Sardine oil loaded vanillic acid grafted chitosan microparticles improves the in vivo anti-oxidant, haematological and lipid profile. J Food Sci Technol 2022; 59:3086-3092.
61. Ashokkumar N, Vinothiya K. Protective impact of vanillic acid on lipid profile and lipid metabolic enzymes in dbetic hypertensive rat model generated by a high-fat diet. Curr Drug Discov Technol 2023; 20:e240223214005.
62. Jung UJ, Choi M-S. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 2014; 15:6184-6223.
63. Kojta I, Chacińska M, Błachnio-Zabielska A. Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients 2020; 12:1305-1323.
64. Zhang L, Sun W, Duan X, Duan Y, Sun H. Promoting differentiation and lipid metabolism are the primary effects for DINP exposure on 3T3-L1 preadipocytes. Environ Pollut 2019; 255:113154.
65. Cho H-H, Jang S-H, Won C, Kim C-H, Kim H-D, Kim TH, et al. Derhamnosylmaysin inhibits adipogenesis via inhibiting expression of PPARγ and C/EBPα in 3T3-L1 cells. Molecules 2022; 27:4232-4245.
66. Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti GA, et al. Adipose tissue dysfunction as determinant of obesity-associated metabolic complications. Int J Mol Sci 2019; 20:2358.
67. Xin F, Cheng Y, Wen X, Zhang J, Shi X, Liu P, et al. BK channel depletion promotes adipocyte differentiation by activating the MAPK/ERK pathway. Stem Cells 2023:sxad082.
68. Vasileva LV, Savova MS, Amirova KM, Balcheva-Sivenova Z, Ferrante C, Orlando G, et al. Caffeic and chlorogenic acids synergistically activate browning program in human adipocytes: Implications of AMPK-and PPAR-mediated pathways. Int J Mol Sci 2020; 21:9740.
69. Hwang M-S, Baek J-H, Song J-K, Lee IH, Chun K-H. Tschimganidine reduces lipid accumulation through AMPK activation and alleviates high-fat diet-induced metabolic diseases. BMB Rep 2023; 56:246.
70. Gwon SY, Ahn J, Jung CH, Moon B, Ha T-Y. Shikonin attenuates hepatic steatosis by enhancing beta oxidation and energy expenditure via AMPK activation. Nutrients 2020; 12:1133.
71. Jung Y, Park J, Kim HL, Sim JE, Youn DH, Kang J, et al. Vanillic acid attenuates obesity via activation of the AMPK pathway and thermogenic factors in vivo and in vitro . FASEB J 2018; 32:1388-1402.
72. Han X, Guo J, You Y, Yin M, Liang J, Ren C, et al. Vanillic acid activates thermogenesis in brown and white adipose tissue. Food Funct 2018; 9:4366-4375.
73. Park J, Cho SY, Kang J, Park WY, Lee S, Jung Y, et al. Vanillic acid improves comorbidity of cancer and obesity through STAT3 regulation in high-fat-diet-induced obese and B16BL6 melanoma-injected mice. Biomolecules 2020; 10:1098.
74. Pechanova O, Varga Z, Cebova M, Giricz Z, Pacher P, Ferdinandy P. Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol 2015; 172:1415-1433.
75.Aggarwal H, Kanuri BN, Dikshit M. Role of iNOS in insulin resistance and endothelial dysfunction. In: Chakraborti S, Dhalla, N., Ganguly, N., Dikshit, M., editor. Oxid Stress Heart Dis. Singapore: Springer; 2019. p. 461-482.
76. Kumar SK, Mani KP. Endocan alters nitric oxide production in endothelial cells by targeting AKT/eNOS and NFkB/iNOS signaling. Nitric Oxide 2021; 117:26-33.
77. Zhou Q, Tu T, Tai S, Tang L, Yang H, Zhu Z. Endothelial specific deletion of HMGB1 increases blood pressure and retards ischemia recovery through eNOS and ROS pathway in mice. Redox Biol 2021; 41:101890.
78. Atawia RT, Toque HA, Meghil MM, Benson TW, Yiew NKH, Cutler CW, et al. Role of arginase in obesity-induced visceral adipose tissue dysregulation and endothelial dysfunction. Int J Mol Sci 2019; 20:1462-1480.
79. Ji L, Su S, Xin M, Zhang Z, Nan X, Li Z, et al. Luteolin ameliorates hypoxia-induced pulmonary hypertension via regulating HIF-2α-Arg-NO axis and PI3K-AKT-eNOS-NO signaling pathway. Phytomedicine 2022; 104:154329.
80. Kumar S, Prahalathan P, Raja B. Antihypertensive and anti-oxidant potential of vanillic acid, a phenolic compound in L-NAME-induced hypertensive rats: A dose-dependence study. Redox Rep 2011; 16:208-215.
81. Kumar S, Prahalathan P, Raja B. Vanillic acid: A potential inhibitor of cardiac and aortic wall remodeling in l-NAME induced hypertension through upregulation of endothelial nitric oxide synthase. Environ Toxicol Pharmacol 2014; 38:643-652.
82. Dianat M, Radmanesh E, Badavi M, Mard SA, Goudarzi G. Disturbance effects of PM₁₀ on iNOS and eNOS mRNA expression levels and anti-oxidant activity induced by ischemia-reperfusion injury in isolated rat heart: Protective role of vanillic acid. Environ Sci Pollut Res Int 2016; 23:5154-5165.
83. Baniahmad B, Safaeian L, Vaseghi G, Rabbani M, Mohammadi B. Cardioprotective effect of vanillic acid against doxorubicin-induced cardiotoxicity in rat. Res Pharm Sci 2020; 15:87-96.
84. Wang S, Sun X, Wang Z, Zhou S, Su S, Nan X, et al. Vanillic acid attenuates monocrotaline-induced pulmonary arterial hypertension by enhancing NO signaling pathways. Nat Prod Commun 2022; 17:1934578X221128411.